Literature DB >> 8152335

An adrenomedullin (ADM) fragment retains the systemic vasodilator activity of human ADM.

Q Hao1, J K Chang, H Gharavi, Y Fortenberry, A Hyman, H Lippton.   

Abstract

The present study was undertaken to investigate the effects of human ADM, a newly discovered peptide present in normal human plasma, as well as a fragment of human ADM, human ADM13-52, on systemic hemodynamics in the anesthetized cat. Intravenous (i.v.) bolus injections of human ADM and human ADM13-52 decreased systemic arterial pressure (SAP) in a dose-dependent manner. Since neither peptide altered cardiac output, the decreases in SAP reflect reductions in systemic vascular resistance. The systemic vasodilator responses to the same doses of human ADM and human ADM13-52 in the cat were similar. The present study demonstrates the systemic vasodilator activity of ADM is conserved across species. The present data suggest that human ADM13-52 or a peptide structurally similar to it may mediate the hemodynamic properties of ADM in vivo in man. Since cardiac output and heart rate were not altered during the marked systemic vasodepressor response to ADM, activation of the ADM vasodilator mechanism may represent a therapeutic alternative in the clinical management of hypertensive diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8152335     DOI: 10.1016/0024-3205(94)00844-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Effects of adrenomedullin and calcitonin gene-related peptide on airway and pulmonary vascular smooth muscle in guinea-pigs.

Authors:  A Pinto; K Sekizawa; M Yamaya; T Ohrui; Y X Jia; H Sasaki
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

2.  Interaction of human adrenomedullin 13-52 with calcitonin gene-related peptide receptors in the microvasculature of the rat and hamster.

Authors:  J M Hall; L Siney; H Lippton; A Hyman; J Kang-Chang; S D Brain
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.